



**MINUTES AND OVERVIEW PLAN
CIBMTR LYMPHOMA WORKING COMMITTEE**

Houston, Texas

Thursday, February 21, 2019, 12:15 – 2:15 pm

Co-Chair: Mohamed Kharfan-Dabaja, MD, MBA, Mayo Clinic, Jacksonville, FL;
Telephone: 904-953-2000; E-mail: kharfandabaja.mohamed@mayo.edu

Co-Chair: Anna Sureda, MD, PhD, Institut Català d'Oncologia, Barcelona, Spain;
Telephone: +34 9326 07353; E-mail: asureda@iconcologia.net

Co-Chair: Timothy Fenske, MD, Medical College of Wisconsin, Milwaukee, WI;
Telephone: 414-805-4633; E-mail: tfenske@mcw.edu

Scientific Director: Mehdi Hamadani, MD, CIBMTR Statistical Center, Milwaukee, WI;
Telephone: 414-805-0700; E-mail: mhamadani@mcw.edu

Statistical Director: Kwang Woo Ahn, PhD, CIBMTR Statistical Center, Milwaukee, WI;
Telephone: 414-456-7387; E-mail: kwooahn@mcw.edu

Statistician: Carlos Litovich, MPH, CIBMTR Statistical Center, Milwaukee, WI;
Telephone: 414-805-0660; E-mail: clitovich@mcw.edu

1. Introduction

The CIBMTR Hodgkin and Non-Hodgkin Lymphoma Working Committee was called to order at 12:15 pm on Thursday, February 21, 2019 by Dr. Mehdi Hamadani. Dr. Anna Sureda introduced the working committee leadership. Dr. Sureda also outlined the Working Committee goals, expectations, and limitations and provided an update on the Working Committee productivity including 5 publications, and 1 oral presentation at the 2019 EBMT meetings, and 3 poster presentations at American Society of Hematology, American Society of Clinical Oncology and 2019 TCT meetings. Dr. Timothy Fenske went over the seven studies in progress and reviewed the voting guidelines. The guidelines are based on a scale from 1 to 9; 1=high scientific impact, 9=low scientific impact. In addition, Dr. Fenske presented the future priority of our studies. Dr. Mehdi Hamadani explained the difference between the TED and CRF data collection forms, the study life cycle, disclosure of conflict of interest and the rules for authorship: 1) substantial and timely contributions to conception and design, or acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; 3) final approval for the version to be published. Dr. Hamadani emphasized that WC authorship is open to any LYWC Tandem Meetings attendees and encouraged junior faculty, fellows and assistant professors to collaborate actively with the Lymphoma Writing Committee.

2. Accrual summary

Dr. Timothy Fenske presented a slide with the accruals, highlighting a change in the past years. It was mentioned that the accrual summary was available in the LYWC materials, attachment 2.

3. Presentations, published or submitted papers

Dr. Timothy Fenske listed the presentations and publications during 2018, highlighting the great

productivity of the LYWC, including the following studies published or presented:

1. **LY06-03** Sureda A, Zhang M-J, Dreger P, Carreras J, Fenske T, Finel H, Schouten H, Montoto S, Robinson S, Smith SM, Boumedil A, Hamadani M, Pasquini MC. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. **Cancer. 2018 Apr 15; 124(8):1733-1742.**
2. **LY16-03** Dreger P, Sureda A, Ahn KW, Eapen M, Litovich C, Finel H, Boumendil A, Gopal A, Herrera AF, Schimid C, Diez-Martin JL, Fuchs E, Bolaños-Meade J, Gooptu M, Al Malki MM, Castagna L, Ciurea SO, Dominetto A, Blaise D, Ciceri F, Tischer J, Corradini P, Montoto S, Robinson S, Gülbas Z, Hamadani M. Outcome of patients who have undergone haploidentical stem cell transplantation for diffuse large B cell lymphoma: A retrospective study of the CIBMTR Lymphoma WC and the EBMT Lymphoma WP (P Dreger/A Sureda) **Blood Advances (In Press).**
3. **LY16-04** Smith SM, Godfrey J, Ahn KW, DiGilio A, Ahmed S, Agrawal V, Bachanova V, Bacher U, Bashey A, Bolaños-Meade J, Cairo M, Chen A, Chhabra S, Copelan E, Dahi PB, Aljurf M, Farooq U, Ganguly S, Hertzberg M, Holmberg L, Inwards D, Kanate AS, Karmali R, Kenkre VP, Kharfan-Dabaja MA, Klein A, Lazarus HM, Mei M, Mussetti A, Nishihori T, Ramakrishnan Geethakumari P, Saad A, Savani BN, Schouten HC, Shah N, Urbano-Ispizua A, Vij R, Vose J, Sureda A, Hamadani M. Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. **Cancer. 2018 Jun 15; 124(12):2541-2551.**
4. **LY17-01** Shah NN, Ahn KW, Litovich C, Fenske TS, Ahmed S, Battiwalla M, Bejanyan N, Dahi PB, Bolaños-Meade J, Chen AI, Ciurea SO, Bachanova V, DeFilipp Z, Epperla N, Farhadfar N, Herrera AF, Haverkos BM, Holmberg L, Hossain NM, Kharfan-Dabaja MA, Kenkre VP, Lazarus HM, Murthy HS, Nishihori T, Rezvani AR, D'Souza A, Savani BN, Ulrickson ML, Waller EK, Sureda A, Smith SM, Hamadani M. Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: A CIBMTR analysis. **Blood Advances. 2018 Apr 24; 2(8):933-940.**
5. **LY17-03** Epperla N, Kwang AW, Litovich C, Kharfan-Dabaja MA, Smith SM, Sureda A, Fenske TS, Hamadani M. Impact of allogeneic hematopoietic cell transplantation on the outcomes of Angioimmunoblastic T-cell lymphoma. **Journal of Hematologic Oncology (In Press).**
6. **LY17-03** Impact of allogeneic hematopoietic cell transplantation on the outcomes of Angioimmunoblastic T-cell lymphoma (N Epperla) **Accepted for oral presentation at the 2018 American Society of Hematology Meeting in San Diego, December 2018.**

4. Studies in progress

Dr. Timothy Fenske presented the studies in progress and gave an overview of the current standing of each study.

7. **LY16-02** Comparison of alternative donor source stem cell transplant versus matched related donor stem cell transplant for Hodgkin lymphoma (S Ahmed/J Kanakry) **Submitted**
8. **LY17-01b** Clinical outcomes of patients age ≥ 65 undergoing allogeneic hematopoietic cell transplant for non-Hodgkin lymphoma (N Shah) **Manuscript Preparation**
9. **LY17-02** Allografts in lymphoma following reduced intensity conditioning (N Ghosh/S Ahmed) **Analysis**
10. **LY18-01** Outcomes in b cell non-Hodgkin lymphoma patients who underwent autologous stem cell transplantation following rituximab containing conditioning regimens (D Jagadeesh/N Majhail/B Hill) **Protocol Development**
11. **LY18-02** Effect of time to relapse on overall survival in mantle cell lymphoma patients following frontline autologous stem cell transplant (P Riedell/S Smith) **Protocol Development**

12. **LY18-03** Does outcome after allogeneic hematopoietic stem cell transplant differ between patients with de novo diffuse large b-cell lymphoma and transformed diffuse large b cell lymphoma arising in the setting of indolent lymphoma (A Herrera) **Protocol Development**
13. **LY18-G1** Maintenance therapies for Hodgkin and non-Hodgkin lymphomas after autologous transplantation: a consensus project of ASBMT, CIBMTR and EBMT (M Hamadani) **Manuscript Preparation**

5. Introduction to TED (Transplant Essential Data) vs CRF (Comprehensive Report Form) (M Hamadani)

Dr. Mehdi Hamadani emphasized the difference between the TED and CRF databases. It was emphasized that CRF is a subset of the TED database, and that the CRF forms collect all disease specific information such as lines of therapy, extranodal involvement, and prior radiation. If a study needs any of this information, CRF level data is needed on the study.

6. Future/proposed studies

1. **PROP 1808-02** Evaluating the efficacy of high-dose therapy and autologous hematopoietic cell transplantation for gray zone lymphoma or aggressive B-cell lymphoma with features intermediate between diffuse large B- cell and Hodgkin lymphoma. (Kharfan-Dabaja, Ayala, Murthy) (Attachment 4) *The optimal treatment for GZL remains undefined. This concept intends to study outcomes of rare disease histology.*
2. **PROP 1809-01** Post-transplant cyclophosphamide-based haploidentical transplantation versus matched sibling or well-matched unrelated donor transplantation for peripheral T-cell Lymphoma: A CIBMTR Lymphoma working committee & EBMT Lymphoma working party analysis (Dreger, Hamadani) (Attachment 5) *This concept intends to compare outcomes for different donor types in PTCL, the most common indication for alloHCT in NHL.*
3. **PROP 1810-02/1811-56** Evaluating the impact of checkpoint inhibitor exposure on the outcomes of allogeneic hematopoietic cell transplantation in patients with Hodgkin lymphoma; Outcomes of allogeneic HCT in patients with Hodgkin lymphoma in the era of checkpoint inhibitors (Awan, Perales, Sureda) (Attachment 6) *This concept pretends to test if results of alloHCT for HL have improved in the recent era due to improvement of post-HCT outcomes through disease relapse, due to prior CPI.*
4. **PROP 1810-07** Autologous transplantation vs allogeneic transplantation in patients with angioimmunoblastic t-cell lymphoma (Epperla) (Attachment 7) *This concept intends to study outcomes of a rare histology of NHL, testing if allogeneic HCT provides durable remission compared to autoHCT.*
5. **PROP 1811-08/1811-191** An evaluation of the use and impact of post-transplant brentuximab vedotin in patients with classical Hodgkin lymphoma; The use of hematopoietic stem cell transplant for Hodgkin lymphoma: an analysis of treatment patterns in the modern era of novel agents (Cohen, Parsons, Kumar, Hahn; Smith) (Attachment 8) *This concept pretends to identify trends of HCT use, and determine if patients undergoing HCT for HL in the novel agent era have improved OS and DFS compared to prior era.*
6. **PROP 1811-19/1811-156** The impact of conditioning regimens on outcomes of autologous hematopoietic stem cell transplantation in peripheral t cell lymphoma; Impact of conditioning regimen on outcomes for patients with peripheral T-cell lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation (Jagadeesh, Majhail, Hu; DHolaria, Savani, Kharfan-Dabaja) (Attachment 9) *This concept aims to evaluate the effect of conditioning regimen on survival of patients with PTCL.*

7. **PROP 1811-40** Hematopoietic stem cell transplantation for relapsed/refractory primary mediastinal b cell lymphoma (Mussetti, Sureda) (Attachment 10) *This concept intends to compare auto vs. alloHCT strategies in outcomes of a new subtype of DLBCL.*
8. **PROP 1811-89/1811-135** Determining the optimal conditioning regimen for patients with primary central nervous system lymphoma undergoing autologous hematopoietic cell transplantation; A comparison of thiotepa and busulfan (TB)-based vs. thiotepa and carmustine (TT-BCNU) conditioned autologous transplantation in the treatment of primary and secondary CNS lymphoma. (Scordo, Sauter; Wang, Jimenez) (Attachment 11) *This concept intends to describe the optimal conditioning regimen for primary CNS lymphoma patients.*
9. **PROP 1811-101** Outcomes in elderly patients (Age ≥ 70 years) received autologous hematopoietic stem cell transplant for non-Hodgkin lymphoma (Zhou, Rabinowitz, Nath) (Attachment 12) *This study aims to study outcomes in elderly NHL patients who received an autoHCT, in comparison with younger cohort.*

19 additional proposals were submitted to the committee but were not presented due to the following reasons:

1. **PROP 1811-06** Outcomes of patients with relapsed/refractory Hodgkin and non-Hodgkin lymphoma treated with radiotherapy in addition to high-dose chemotherapy and stem cell transplantation. *Dropped with current CIBMTR study.*
2. **PROP 1811-25** Rate of large granular lymphocytosis in SCT and effect on the long-term prognosis of post-transplant patients. *Dropped due to feasibility.*
3. **PROP 1811-37** Clinical outcome of patients 50 years and older with Hodgkin lymphoma receiving allogeneic hematopoietic stem cell transplantation. *Dropped due to feasibility.*
4. **PROP 1811-48** Evaluating the efficacy of high-dose therapy and autologous hematopoietic cell transplantation for primary effusion lymphoma. *Dropped due to feasibility.*
5. **PROP 1811-61** Impact of allogeneic hematopoietic cell transplantation on the outcomes of adult T cell Leukemia Lymphoma. *Dropped due to feasibility.*
6. **PROP 1811-65** Does BV maintenance after autoHCT decrease the chance and success of alloHCT in high risk HL patients. *Dropped due to feasibility.*
7. **PROP 1811-70** Role of consolidation therapy post auto transplant in T cell lymphomas. *Dropped due to feasibility.*
8. **PROP 1811-76** Outcomes of auto compared to allo transplants for diagnosis of high risk non-Hodgkin lymphoma. *Dropped due to feasibility.*
9. **PROP 1811-80** Outcomes of long-term survivors of non-Hodgkin lymphoma who underwent reduced intensity alloHCT: matched unrelated vs haploidentical donor (Dholaria, Savani, Kharfan-Dabaja). *Dropped due to feasibility.*
10. **PROP 1811-91** Evaluation of outcomes of patients with B-PLL undergoing allogeneic stem cell transplant. *Dropped due to feasibility.*
11. **PROP 1811-111** Clinical and pathologic factors predictive of refractoriness or early relapse (<12 months) to autologous stem cell transplant in patients with primary refractory DLBCL. *Dropped due to feasibility.*
12. **PROP 1811-122** The impact of adding Rituximab to BEAM conditioning for patients with DLBCL undergoing autoHCT. *Dropped due to overlap with current CIBMTR study (LY18-01).*
13. **PROP 1811-140** Donor and recipient t cell exhaustion markers before allogeneic transplantation in Hodgkin lymphoma. *Dropped due to feasibility.*
14. **PROP 1811-152** Survival after autologous and allogeneic stem cell transplantation in peripheral T-cell lymphoma. *Dropped due to overlap with current CIBMTR study (LY06-05).*

15. **PROP 1811-164** Outcomes of autologous hematopoietic stem cell transplantation in primary effusion lymphoma. *Dropped due to small sample size.*
16. **PROP 1811-181** Hematopoietic cell transplantation outcomes for cutaneous T cell lymphoma. *Dropped due to overlap with current CIBMTR study (LY06-05).*
17. **PROP 1811-182** For post-transplant cyclophosphamide-based GVHD prophylaxis, is survival after matched unrelated donor allogeneic transplantation better than haploidentical transplantation for relapsed lymphomas. *Dropped due to feasibility.*
18. **PROP 1811-183** Retrospective study of blood or bone marrow transplantation for enteropathy-associated T-cell lymphoma and hepatosplenic T-cell lymphoma. *Dropped due to feasibility.*
19. **PROP 1812-11** To evaluate outcomes of HSCT with TBI vs. Flu/Mel conditioning in treatment of cutaneous T-cell lymphoma. *Drooped due to overlap with current CIBTMR study (LY17-02).*

7. Other Business

After the proposals were presented, the voting process was reiterated, and each participant had the opportunity to rate each new proposal using paper ballots. Without additional comments, the meeting was adjourned at 1:52 pm.

Working Committee Overview Plan for 2019-2020

Study number and title	Current status	Goal with date	Total hours to complete	Total hours to goal	Hours allocated to 6/30/2019	Hours allocated 7/1/2019-6/30/2020	Total Hours allocated
LY17-02 Allografts in lymphoma following reduced intensity conditioning.	Analysis	Submission – 6/30/2019	150	150	150	0	150
LY18-01 Outcomes in B-cell non-Hodgkin's lymphoma patients who underwent autologous stem cell transplantation following rituximab containing conditioning Regimens.	Data file preparation	Manuscript preparation – 6/30/2019	230	160	160	70	230
LY18-02 Effect of time to relapse on overall survival in mantle cell lymphoma patients following frontline autologous stem cell transplant.	Draft protocol received	Data file preparation – 6/30/2019	310	60	60	250	310
LY18-03 Transplantation for CLL undergoing Richter's transformation arising in the setting of indolent lymphoma.	Protocol development	Data file preparation – 6/30/2019	290	20	20	200	220
LY19-01 Post-transplant cyclophosphamide-based haploidentical transplantation versus matched sibling or well-matched unrelated donor transplantation for peripheral T-cell lymphoma: a CIBMTR lymphoma working committee and EBMT lymphoma working party analysis.	Protocol pending	Manuscript preparation – 7/1/2020	330	260	0	260	260

LY19-02 Determining the optimal conditioning regimen for patients with primary central nervous system lymphoma undergoing autologous hematopoietic cell transplantation.	Protocol pending	Data file preparation – 7/1/2020	330	100	0	100	100
---	------------------	----------------------------------	-----	-----	---	-----	-----

Oversight Assignments for Working Committee Leadership (March 2019)

Anna Sureda

LY17-02 Allografts in lymphoma following reduced intensity conditioning.

Timothy Fenske

LY18-01 Outcomes in B-cell non-Hodgkin's lymphoma patients who underwent autologous stem cell transplantation following rituximab containing conditioning Regimens.

LY18-02 Effect of time to relapse on overall survival in mantle cell lymphoma patients following frontline autologous stem cell transplant.

Mohamed Kharfan-Dabaja

LY18-03 Transplantation for CLL undergoing Richter's transformation arising in the setting of indolent lymphoma.

Craig Sauter

LY19-02 Determining the optimal conditioning regimen for patients with primary central nervous system lymphoma undergoing autologous hematopoietic cell transplantation.

Mehdi Hamadani

LY19-01 Post-transplant cyclophosphamide-based haploidentical transplantation versus matched sibling or well-matched unrelated donor transplantation for peripheral T-cell lymphoma: a CIBMTR lymphoma working committee and EBMT lymphoma working party analysis.